Biogen prices new MS drug at discount to key competitors

WASHINGTON (Reuters) - Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday.

via Reuters: Health News Read More Here..